COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena explores coca leaf's therapeutic benefits for ADHD and neuropsychiatric indications in partnership with Peru. Jaguar's Dr. King to present at Wisdom of the Leaf Coca Summit on coca-based Botanical Drugs -
-
-
COMMUNIQUÉ DE PRESSE
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Jaguar Health, Inc. initiates Phase 2 study for crofelemer, a novel plant-based drug, in pediatric MVID patients. Study aims to evaluate drug efficacy for rare diseases MVID and SBS-IF -
-
-
COMMUNIQUÉ DE PRESSE
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
World Health Organization (WHO) elevates cholera to highest emergency level due to global resurgence. Crofelemer granted orphan-drug designation by FDA and EMA for cholera treatment
